Morgan Stanley Downgrades QIAGEN to Equalweight From Overweight, Cuts Price Target to $48 From $50

USA
EnglishUK
EnglishIndia
EnglishAustralia
EnglishCanada
EnglishFrance
FrançaisSuisse
FrançaisEspaña
EspañolDeutschland
DeutschÖsterreich
DeutschSchweiz
DeutschBelgië
NederlandsNederland
NederlandsItalia
ItalianoSverige
Svenska
Market Closed -
Other stock markets
|
Pre-market 09:08:19 am | |||
40.06 USD | -0.20% |
|
40.12 | +0.15% |
07:01am | QIAGEN NV : Deutsche Bank keeps its Buy rating | ZD |
Feb. 13 | Qiagen Strengthens Global Bioinformatics Leadership With New Data Center In Australia/Asia-Pacific Region | RE |